ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
Public ClinicalTrials.gov record NCT00936676. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects Who Participated in the ADAGIO Study
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Eligible participants, who participated in the ADAGIO trial and who sign an approved informed consent form, will be enrolled into the study at their original study locations. participants who have stopped rasagiline therapy and in the opinion of the investigator will gain clinical benefit from restarting treatment can also be considered for enrollment in the Core follow-up study period. Use of any other anti-PD treatment is permitted as deemed necessary by the treating physician (according to the participants clinical status).
Study identification
- NCT ID
- NCT00936676
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 684 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2009 (Type not available)
- Primary completion
- Mar 2013 (Actual)
- Completion
- Mar 2013 (Actual)
- Last update posted
- Apr 11, 2016
2009 – 2013
United States locations
- U.S. sites
- 37
- U.S. states
- 20
- U.S. cities
- 35
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 7054 | Birmingham | Alabama | — | — |
| Teva Investigational Site 7006 | Tucson | Arizona | — | — |
| Teva Investigational Site 7018 | Irvine | California | — | — |
| Teva Investigational Site 7019 | La Jolla | California | — | — |
| Teva Investigational Site 7039 | Loma Linda | California | — | — |
| Teva Investigational Site 7023 | Los Angeles | California | — | — |
| Teva Investigational Site 7022 | Sunnyvale | California | — | — |
| Teva Investigational Site 7024 | Danbury | Connecticut | — | — |
| Teva Investigational Site 7016 | Farmington | Connecticut | — | — |
| Teva Investigational Site 7020 | Boca Raton | Florida | — | — |
| Teva Investigational Site 7011 | Gainesville | Florida | — | — |
| Teva Investigational Site 7045 | Miami | Florida | — | — |
| Teva Investigational Site 7017 | Tampa | Florida | — | — |
| Teva Investigational Site 7055 | Atlanta | Georgia | — | — |
| Teva Investigational Site 7043 | Augusta | Georgia | — | — |
| Teva Investigational Site 7013 | Chicago | Illinois | — | — |
| Teva Investigational Site 7052 | Chicago | Illinois | — | — |
| Teva Investigational Site 7001 | Northbrook | Illinois | — | — |
| Teva Investigational Site 7008 | Springfield | Illinois | — | — |
| Teva Investigational Site 7037 | Des Moines | Iowa | — | — |
| Teva Investigational Site 7053 | Scarborough | Maine | — | — |
| Teva Investigational Site 7026 | Boston | Massachusetts | — | — |
| Teva Investigational Site 7015 | Lansing | Michigan | — | — |
| Teva Investigational Site 7010 | Traverse City | Michigan | — | — |
| Teva Investigational Site 7029 | Golden Valley | Minnesota | — | — |
| Teva Investigational Site 7004 | Omaha | Nebraska | — | — |
| Teva Investigational Site 7046 | Buffalo | New York | — | — |
| Teva Investigational Site 7048 | Durham | North Carolina | — | — |
| Teva Investigational Site 7051 | Raleigh | North Carolina | — | — |
| Teva Investigational Site 7034 | Cincinnati | Ohio | — | — |
| Teva Investigational Site 7009 | Toledo | Ohio | — | — |
| Teva Investigational Site 7002 | Allentown | Pennsylvania | — | — |
| Teva Investigational Site 7044 | Philadelphia | Pennsylvania | — | — |
| Teva Investigational Site 7050 | Providence | Rhode Island | — | — |
| Teva Investigational Site 7035 | Houston | Texas | — | — |
| Teva Investigational Site 7056 | Houston | Texas | — | — |
| Teva Investigational Site 7025 | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 65 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00936676, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 11, 2016 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00936676 live on ClinicalTrials.gov.